Supplementary Figure 1. Tracheal secretion from COVID-19 patients with DM trends toward increased expression of ALOX5 and ACE2/TMPRSS2 viral receptors. Relative expression of ACE2 (A), TMPRSS2 (B) and ALOX5 (C) in tracheal secretion of NDM and DM patients with COVID-19. Dotted line = control group relarive expression. Data shown as median.

Supplementary Figure 2. No correlation between ACE2 and ALOX5 is observed in NDM COVID-19 patients. Correlation between the expression of ALOX5 and ACE2 in PBMCs of NDM individuals with COVID-19 (A). Spearman r correlation.

Supplementary Figure 3. No difference in IL-1 β production between NDM and DM groups of patients with COVID-19. IL- β serum levels in NDM and DM individuals with COVID-19. Dotted line = cut-off for detection limit. Data shown as median.

Supplementary Figure 4. LTB4 is the most prevalent inflammatory mediator at systemic levels. Global and individualized view of LTB4 (red), IL-6 (green) and TNF- α (blue) production in NDM (A) and DM (B) individuals with COVID-19 through Cubic spline analysis.

Supplementary Figure 5. O₂ saturation levels are reduced in DM patients with COVID-19 compared with NDM individuals. SpO2 in NDM and DM patients with COVID-19. Data shown as median. * p<0.05.

Supplementary Figure 6. Correlation between inflammatory mediators and clinical parameters of NDM and DM individuals with COVID-19. Correlation between ALOX5 and LTB₄ (A), PaO_2/FiO_2 and SpO_2/FiO_2 (B), disease duration and hospitalization days (C), IL-6 and hospitalization days (D), TNF- α and LTB₄ (E) in NDM and DM patients with COVID-19. Dotted lines = median of NDM group. Spearman r correlation. * p<0.05. **** p<0.0001.

Supplementary Figure 7. Liver enzymes are altered in DM patients with COVID-19 compared to NDM group. Quantification of Leucogram (A), platelets (B), C-reactive protein (C), Lactate dehydrogenase (D), Glutamic-oxalacetic Transaminase (E), Glutamic

Pyruvic Transaminase (F), Gamma-glutamyl transferase (G), Alkaline phosphatase (H), Lactate (I), Urea (J) and Creatinine (K) in NDM and DM patients with COVID-19. Data shown in median. * p<0.05.